PetMeds Reports 19.4% Sales Decline in Fiscal Q2 as Net Loss Narrows to $6.4 Million

PetMed Express reported second-quarter fiscal 2027 net sales of $35.8 million, down 19.4% year over year, while its net loss narrowed to $6.4 million from $8.5 million. Adjusted EBITDA declined to negative $3.6 million as the company focused on reducing operating costs and repositioning its direct-to-consumer pet pharmacy business.
  • PetMeds reported second-quarter net sales of $35.8 million, compared with $44.4 million a year earlier, representing a 19.4% decline.
  • Quarterly net loss narrowed to $6.4 million, or $(0.31) per diluted share, compared with $8.5 million, or $(0.41) per diluted share, in the prior-year period.
  • Adjusted EBITDA was negative $3.6 million, compared with negative $2.3 million a year earlier.
  • Lower prescription medication sales and increased consumer promotional usage contributed to the revenue decline.
  • General and administrative expenses and advertising expenses decreased compared with the prior-year quarter.
  • PetMeds reported a 32% year-over-year reduction in its cost to acquire a new customer as it works to improve marketing efficiency and profitability.

PetMed Express, Inc., operating as PetMeds and parent company of PetCareRx (NASDAQ: PETS), reported lower revenue but a narrower net loss for its second quarter ended September 30, 2026, as the online pet pharmacy continues efforts to stabilize operations and improve profitability.

Net sales declined 19.4% to $35.8 million from $44.4 million in the comparable prior-year period. The company attributed the decrease primarily to lower prescription medication sales and increased use of consumer promotions.

Despite the revenue decline, PetMeds reduced its quarterly net loss to $6.4 million, compared with $8.5 million a year earlier. The improvement was primarily driven by lower general and administrative expenses and advertising spending.

However, adjusted EBITDA, a non-GAAP measure, declined to negative $3.6 million from negative $2.3 million in the prior-year quarter, reflecting continued pressure on operating performance.

Second-Quarter Financial Performance

PetMeds reported the following financial results for the three months ended September 30, 2026, compared with the corresponding prior-year period.

Financial metric Q2 FY2027 Q2 FY2026
Net sales $35.770M $44.364M
Gross profit $9.803M $12.415M
General & administrative expenses $11.968M $14.176M
Advertising expenses $2.072M $4.341M
Operating loss $(6.419)M $(8.380)M
Net loss $(6.434)M $(8.520)M
Loss per diluted share $(0.31) $(0.41)
Adjusted EBITDA $(3.643)M $(2.316)M

Figures are presented in millions of U.S. dollars, converted from the company’s financial statements reported in thousands. Parentheses indicate losses or negative values. Adjusted EBITDA is a non-GAAP measure.

Revenue Decline and Cost Reductions Shape Quarterly Results

PetMeds’ quarterly gross profit decreased to $9.8 million from $12.4 million in the prior-year period.

The company attributed the lower gross profit primarily to an unfavorable product mix shift and lower manufacturer rebates as a percentage of sales. These pressures were partially offset by lower net freight costs per order.

Operating expenses declined to $16.2 million from $20.8 million a year earlier.

General and administrative expenses decreased to $12.0 million from $14.2 million, while advertising expenses declined to $2.1 million from $4.3 million.

These reductions helped narrow the company’s operating loss to $6.4 million from $8.4 million in the prior-year quarter.

Nevertheless, adjusted EBITDA remained negative and deteriorated year over year, reflecting the ongoing challenge of improving operating performance amid lower sales.

Six-Month Results Show Continued Revenue Pressure

For the six months ended September 30, 2026, PetMeds reported net sales of $76.8 million, compared with $95.5 million in the corresponding prior-year period.

The company’s six-month net loss was $12.6 million, compared with $42.7 million a year earlier.

The prior-year six-month period included a $27.3 million impairment of goodwill and intangible assets, while no corresponding impairment was reported in the current period.

Adjusted EBITDA for the first six months of fiscal 2027 was negative $7.1 million, compared with negative $5.0 million in the prior-year period.

The results reflect a reduction in reported net losses alongside continued pressure on revenue and adjusted operating performance.

Cash Position and Balance Sheet

PetMeds reported cash and cash equivalents of $11.4 million as of September 30, 2026, compared with $21.4 million as of March 31, 2026.

For the six months ended September 30, 2026, net cash used in operating activities totaled $8.7 million, compared with $14.4 million in the prior-year period.

The company reported total assets of $59.4 million as of September 30, 2026, compared with $81.2 million at the end of March 2026.

Total shareholders’ equity was $16.9 million, compared with $28.9 million at March 31, 2026.

Inventory balances decreased to $6.3 million from $13.6 million over the same period.

These figures highlight the company’s reduced cash balance and asset base as it continues its operational restructuring and profitability initiatives.

Management Focuses on Customer Acquisition and Profitability

PetMeds CEO and President Jeff Willard said the company has stabilized its operations and is now concentrating on transforming its core direct-to-consumer pharmacy business.

“We have stabilized the operations of the business and our focus now is on transforming our core direct-to-consumer pharmacy business and making PetMeds a leaner, more profitable company at the size we are today,” Willard said.

According to Willard, PetMeds reduced its cost to acquire a new customer by 32% compared with the prior-year quarter.

The company’s next priorities include repositioning the PetMeds brand, improving marketing effectiveness, simplifying the online purchasing experience and increasing customer retention.

Management described these efforts as steps toward building a more profitable business capable of returning to growth.

Outlook for the Online Pet Pharmacy Business

PetMeds operates a nationwide direct-to-consumer pet pharmacy serving dog, cat and horse owners through its PetMeds and PetCareRx brands.

The company offers prescription and generic medications, compounded pharmaceuticals, over-the-counter supplements and nutritional products.

Its fiscal second-quarter results reflect the challenges facing its core pharmacy business, including declining prescription medication sales and increased promotional activity.

Although expense reductions contributed to a narrower GAAP net loss, adjusted EBITDA remained negative and declined compared with the prior-year period.

PetMeds’ stated strategy centers on improving customer acquisition efficiency, strengthening customer retention and aligning operating costs with its current business size.

The company did not provide numerical revenue or earnings guidance in the November 10 earnings announcement.

Full Financial Report: PetMeds Investor Relations — Financial Results and SEC Filings

Information sourced from PetMed Express, Inc.’s November 10, 2026, second-quarter financial results announcement and accompanying financial statements. Adjusted EBITDA is a non-GAAP financial measure and should be considered alongside, rather than as a substitute for, GAAP results.

Never Miss an Animal Health Story

Sign up for free to receive the latest veterinary news, product announcements, and industry developments.